ESC 365 - Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study

ESC Professional Premium Access

Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study

Session: Lipids - Drug therapy 2

Topic: Drug therapy

Speaker: Doctor R. Alonso (SANTIAGO, CL)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Rodrigo Alonso

CENTER FOR ADVANCED METABOLIC MEDICINE AND NUTRITION, SANTIAGO (Chile)

0 follower

6 more presentations in this session

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Speaker: Doctor A. Cordero (Elche, ES)

Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients

Speaker: Doctor J. Katzmann (Leipzig, DE)

Effect of SLCO1B1 genotypes on statin intolerance and response to statins

Speaker: Mrs L. Davis (Harefield, GB) Doctor T. Khan (Harefield, GB)

LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study

Speaker: Professor K. Ray (London, GB)

Trends in management of cardiovascular risk factors in young adults who go on to develop coronary artery disease

Speaker: Doctor D. Vikulova (Vancouver, CA)

Access the full session

Lipids - Drug therapy 2

Speakers: Doctor R. Alonso, Doctor A. Cordero, Doctor J. Katzmann, Mrs L. Davis, Doctor T. Khan...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources